New Drug ApprovalFDA Approves VYBRIQUE as First Oral Film for Erectile Dysfunction FDA Approves VYBRIQUE as First Oral Film for Erectile Dysfunction Read Post »
New Drug ApprovalAbbVie Seeks FDA, EMA Approval of RINVOQ in Vitiligo AbbVie Seeks FDA, EMA Approval of RINVOQ in Vitiligo Read Post »
Health TidingsEli Lilly Q4 2025: Mounjaro and Zepbound Fuel 43% Growth Eli Lilly Q4 2025: Mounjaro and Zepbound Fuel 43% Growth Read Post »
Clinical TrailsUCB’s BIMZELX Achieves 3-Year HS Control: BE HEARD Trial Data Reveale... UCB’s BIMZELX Achieves 3-Year HS Control: BE HEARD Trial Data Reveale... Read Post »
Clinical TrailsFDA Fast Tracks Cumberland’s Ifetroban for DMD Heart Disease FDA Fast Tracks Cumberland’s Ifetroban for DMD Heart Disease Read Post »
Clinical TrailsAstellas Fezolinetant Cuts Menopausal VMS in Japan Phase 3 Astellas Fezolinetant Cuts Menopausal VMS in Japan Phase 3 Read Post »
Clinical TrailsImmunityBio Launches Phase 2 ResQ215B Trial for Indolent B-Cell Lymphoma ImmunityBio Launches Phase 2 ResQ215B Trial for Indolent B-Cell Lymphoma Read Post »
Health TidingsValneva and Butantan Start IXCHIQ Chikungunya Vaccination Pilot in Brazil Valneva and Butantan Start IXCHIQ Chikungunya Vaccination Pilot in Brazil Read Post »
ResearchJohnson & Johnson Calls Out Surgeon Mental Health Crisis Johnson & Johnson Calls Out Surgeon Mental Health Crisis Read Post »
Health TidingsNovo Nordisk Reports 10% Sales Growth in 2025 as Wegovy Pill Launch Strengt... Novo Nordisk Reports 10% Sales Growth in 2025 as Wegovy Pill Launch Strengt... Read Post »
Clinical TrailsNovo Nordisk’s CagriSema Outperforms Semaglutide in REIMAGINE 2 Trial Novo Nordisk’s CagriSema Outperforms Semaglutide in REIMAGINE 2 Trial Read Post »
Health TidingsSPARC’s Sezaby Approval Unlocks Rare Pediatric Priority Review Voucher SPARC’s Sezaby Approval Unlocks Rare Pediatric Priority Review Voucher Read Post »
New Drug ApprovalBayer’s Nubeqa Approved for mHSPC in China Bayer’s Nubeqa Approved for mHSPC in China Read Post »
Clinical TrailsPfizer Bets Big on Monthly GLP-1 After Metsera Deal, VESPER-3 Hits Key Endp... Pfizer Bets Big on Monthly GLP-1 After Metsera Deal, VESPER-3 Hits Key Endp... Read Post »
Health TidingsAstraZeneca Faces FDA Delay for At-Home Saphnelo SC in SLE AstraZeneca Faces FDA Delay for At-Home Saphnelo SC in SLE Read Post »
Clinical TrailsJohnson & Johnson Unveils Real-World Data: ERLEADA Cuts Death Risk by 5... Johnson & Johnson Unveils Real-World Data: ERLEADA Cuts Death Risk by 5... Read Post »
Health TidingsFDA Issues Complete Response Letter for Anaphylm Sublingual Epinephrine Fil... FDA Issues Complete Response Letter for Anaphylm Sublingual Epinephrine Fil... Read Post »
Clinical TrailsPositive Topline Results: Venglustat Succeeds in Sanofi’s LEAP2MONO GD3 S... Positive Topline Results: Venglustat Succeeds in Sanofi’s LEAP2MONO GD3 S... Read Post »
Policy & AcquisitionsIllumina Completes Acquisition of SomaLogic Illumina Completes Acquisition of SomaLogic Read Post »
New Drug ApprovalImfinzi Boosts Survival in Gastric Cancer, Gains CHMP Endorsement Imfinzi Boosts Survival in Gastric Cancer, Gains CHMP Endorsement Read Post »
Clinical TrailsLundbeck INFUSE Study: Vyepti Shines for Hard-to-Treat Migraine Lundbeck INFUSE Study: Vyepti Shines for Hard-to-Treat Migraine Read Post »
Health TidingsFDA Issues CRL for Pharming’s Joenja in Pediatric APDS Patients FDA Issues CRL for Pharming’s Joenja in Pediatric APDS Patients Read Post »
New Drug ApprovalCHMP Backs Rezurock for Chronic GVHD After Re-Examination CHMP Backs Rezurock for Chronic GVHD After Re-Examination Read Post »
New Drug ApprovalIncyte’s Zynyz Wins Positive CHMP Opinion in Advanced Anal Cancer Incyte’s Zynyz Wins Positive CHMP Opinion in Advanced Anal Cancer Read Post »
ResearchMigraine Attacks Disrupt Relationships, AbbVie Report Migraine Attacks Disrupt Relationships, AbbVie Report Read Post »
